Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.54 EPS, expectations were $-0.54. Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Inc. (APLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 11,357,425 | $667,589,442 | +2% | 16.88% |
| 2. | VenBio Select Advisor Kurt Von Emster | 11,111,111 | $653,111,105 | 7.61% | |
| 3. | Octagon Capital Advisors Ting Jia | 2,806,980 | $164,994,284 | 19.77% | |
| 4. | OrbiMed Advisors Samuel Isaly | 1,297,800 | $76,284,684 | +41% | 1.39% |
| 5. | Citadel Investment Group Ken Griffin | 1,186,082 | $69,717,900 | +316% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 250,000 | Large Shareholder | 12,806,342 | 2021-11-18 | Filing | |
| $31.81 | 5,000 | Director | 5,000 | 2020-05-08 | Filing | |
| $37.00 | 540,540 | Large Shareholder | 12,556,342 | 2020-01-13 | Filing | |
| $29.71 | 11,699 | Officer | 11,699 | 2019-08-29 | Filing | |
| $17.00 | 441,176 | Large Shareholder | 12,015,802 | 2019-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.63 | 1,695 | 136,998 | 2024-06-21 | Filing | ||
| $39.22 | 35,305 | 138,693 | 2024-06-21 | Filing | ||
| $44.03 | 100 | Officer | 1,115,983 | 2024-05-08 | Filing | |
| $42.85 | 22,472 | Officer | 1,116,083 | 2024-05-08 | Filing | |
| $42.15 | 56,335 | Officer | 1,138,555 | 2024-05-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,445,290 | $984,415,060 | 0.18% | |
| 2. | 9,555,678 | $572,002,885 | 0.01% | |
| 3. | 5,381,253 | $322,121,807 | 0% | |
| 4. | 3,275,922 | $196,096,693 | 0.14% | |
| 5. | 3,097,141 | $185,394,859 | 0.01% |
News See All
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.73 EPS, expectations were $-0.66. Apellis Pharmaceuticals, Inc.
Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks
In this article, we discuss the 5 stocks receiving price-target cut from analysts.
5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
Below we present the list of 5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2023 Earnings Call Transcript
Operator: Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Third Quarter 2023 Earnings Conference Call.
Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price Targets
In this article, we discuss the 5 stocks receiving price-target hike from Wall Street analysts.
Hedge Fund and Insider Trading News: Odey Asset Management, Greenlight Capital, Brevan Howard Asset Management, Avoro Capital Advisors, Tidewater Inc (TDW), Vistagen Therapeutics, Inc. (VTGN), and More
Brevan Howard Asset Management has appointed Oualid Lahsini as chief executive officer of its Middle East business. Lahsini, who was previously a partner at Ares Management Corp.
5 Worst Performing Healthcare Stocks in 2023
In this article, we discuss 5 worst performing healthcare stocks in 2023.
5 Oversold Healthcare Stocks to Buy
Root, Switzerland-based NovoCure Limited (NASDAQ:NVCR) is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization...
Billionaire Hedge Funds
